Compact fully automated genetic testing system for use “near the patient”
First written in FY2016. 3 of 8 entries say "Advanced", first in FY2018. Latest entry: FY2021.
2 other companies' latest entry also says "Advanced".
- FY2021AdvancedAnnual report
「In March 2021, we launched as in vitro diagnostic products the Simprova Respiratory Virus Panel SARS-CoV-2, FluA, FluB, which simultaneously detects novel coronavirus and seasonal influenza viruses, and the Simprova Mycobacteriosis Panel MTB, MAI, which simultaneously detects tuberculosis bacteria and nontuberculous mycobacteria.」
For Simprova, the Respiratory Virus Panel and Mycobacteriosis Panel were launched in March 2021, expanding the product lineup. - FY2020AchievedAnnual report
「We developed a compact fully automated genetic testing system to address the medical need described as “Near the patient” and launched the Fully Automated Nucleic Acid Testing Device Simprova, the Simprova Respiratory Infection Panel BP,LP,MP and the Simprova Extraction Kit/S1 in April 2020.」
The project progressed from substantial completion of device development and the marketing approval application stage to the launch of Simprova-related products. - FY2019AdvancedAnnual report
「We advanced development of the device and multi-target genetic testing chips for the compact fully automated genetic testing system (Simprova), which addresses the medical need described as “Near the patient,” and began submitting applications for marketing approval for respiratory infection targets on a rolling basis from June 2018. We will continue working toward an early launch.」
Simprova advanced to the marketing approval application stage following substantial completion of device development, and efforts toward the early launch of respiratory infection targets continue. - FY2018AdvancedAnnual report
「We continued working toward commercialization of the compact fully automated genetic testing system (Simprova), which addresses the medical need described as “Near the patient” and initially targets respiratory infections. As device development was largely completed by the end of the consolidated fiscal year, we will continue working toward an early launch.」
For Simprova, device development was largely completed and the project advanced to the stage of preparing for an early launch. - FY2018-Q3RestatedAnnual report
「In terms of earnings, recognition of development costs for the compact fully automated genetic testing device, scheduled for the second quarter, was deferred to the fourth quarter, while efforts to use expenses efficiently also contributed. Operating income was ¥3,504 million, up 3.6% year on year; ordinary income was ¥3,568 million, up 3.0%; and profit attributable to owners of the parent was ¥2,536 million, up 2.5%.」
The deferral of recognition of development costs for the compact fully automated genetic testing device from the scheduled second quarter to the fourth quarter continued. No withdrawal of the development plan was reported. - FY2018-Q2Deferral of the timing of development cost recognitionAnnual report
「In terms of earnings, recognition of development costs for the compact fully automated genetic testing device, scheduled for the second quarter, was deferred to the fourth quarter. However, the cost of sales ratio rose due to higher manufacturing costs for in-house products and changes in the product sales mix, while selling, general and administrative expenses increased, mainly because of other research and testing expenses. As a result, operating income was ¥2,215 million, down 4.7% year on year; ordinary income was ¥2,255 million, down 3.8%; and profit attributable to owners of the parent was ¥1,633 million, down 4.7%.」
Recognition of development costs for the compact fully automated genetic testing device was deferred from the scheduled second quarter to the fourth quarter. No withdrawal of the development plan itself was reported. - FY2017RestatedAnnual report
「To address the medical need described as “Near the patient,” we are working toward early commercialization of a compact fully automated genetic testing device and a multi-target genetic testing chip, initially targeting respiratory infections.」
The policy of pursuing early commercialization of a compact fully automated genetic testing system initially targeting respiratory infections continues. - FY2016First statedAnnual report
「To address the medical need described as “Near the patient,” we are working toward early commercialization of a compact fully automated genetic testing device and a multi-target genetic testing chip, initially targeting respiratory infections.」
This is a development project targeting early commercialization, initially for respiratory infections.